These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19946604)

  • 21. Liposomal temozolomide drug delivery using convection enhanced delivery.
    Nordling-David MM; Yaffe R; Guez D; Meirow H; Last D; Grad E; Salomon S; Sharabi S; Levi-Kalisman Y; Golomb G; Mardor Y
    J Control Release; 2017 Sep; 261():138-146. PubMed ID: 28666727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
    van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
    Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretreatment but not subsequent coincubation with midazolam reduces the cytotoxicity of temozolomide in neuroblastoma cells.
    Braun S; Bauer I; Pannen B; Werdehausen R
    BMC Anesthesiol; 2015 Oct; 15():151. PubMed ID: 26475338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LncRNA-XIST interacts with
    Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y
    Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of temozolomide in hormone-refractory prostate cancer.
    van Brussel JP; Busstra MB; Lang MS; Catsburg T; Schröder FH; Mickisch GH
    Cancer Chemother Pharmacol; 2000; 45(6):509-12. PubMed ID: 10854140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
    Caporali S; Alvino E; Starace G; Ciomei M; Brasca MG; Levati L; Garbin A; Castiglia D; Covaciu C; Bonmassar E; D'Atri S
    Pharmacol Res; 2010 May; 61(5):437-48. PubMed ID: 20026273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
    Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
    J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temozolomide: mechanisms of action, repair and resistance.
    Zhang J; Stevens MF; Bradshaw TD
    Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
    Sun Q; Pei C; Li Q; Dong T; Dong Y; Xing W; Zhou P; Gong Y; Zhen Z; Gao Y; Xiao Y; Su J; Ren H
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1040-1046. PubMed ID: 29366782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
    Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
    Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(β-L-malic acid).
    Patil R; Portilla-Arias J; Ding H; Inoue S; Konda B; Hu J; Wawrowsky KA; Shin PK; Black KL; Holler E; Ljubimova JY
    Pharm Res; 2010 Nov; 27(11):2317-29. PubMed ID: 20387095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multifaceted resistance of gliomas to temozolomide.
    Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
    Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
    Jiang G; Li R; Tang J; Ma Y; Hou X; Yang C; Guo W; Xin Y; Liu Y
    Oncol Rep; 2017 Feb; 37(2):995-1001. PubMed ID: 28035395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
    Zeng H; Yang Z; Xu N; Liu B; Fu Z; Lian C; Guo H
    Cell Death Dis; 2017 Jun; 8(6):e2885. PubMed ID: 28617438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
    Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
    PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
    Fateh S; Schell TD; Gingrich R; Neves RI; Drabick JJ
    Cancer Biol Ther; 2010 Dec; 10(11):1091-7. PubMed ID: 20930514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.